Amplatzer versus Figulla occluder for transcatheter patent foramen ovale closure

Daniela Trabattoni, Achille Gaspardone, Gregory Angelo Sgueglia, Franco Fabbiocchi, Gaetano Gioffrè, Piero Montorsi, Giuseppe Calligaris, Maria Iamele, Antonella De Santis, Antonio L Bartorelli

Research output: Contribution to journalArticlepeer-review


AIMS: To compare in a observational study acute and 12-month results of percutaneous closure of patent foramen ovale (PFO) with two occluder devices.

METHODS AND RESULTS: Between June 2007 and October 2014, 406 consecutive patients (48.1±13.3 years, 243 women) underwent percutaneous PFO closure either with the Amplatzer (n=179) or the Figulla (n=227) device after a stroke or a transient ischemic attack ascribed to the PFO. A right-to- left shunt grade >1 was previously detected in all patients and atrial septal aneurysm was present in 111 (27.5%) patients. Patients were followed-up with contrast transthoracic echocardiogram and clinically at 24-hour, six-month, and twelve-months after the procedure. A high procedural success was observed in both groups. Despite a trend towards a higher incidence of acute residual shunt immediately after device deployment among Figulla occluder patients, a residual grade ≥2 right-to- left shunt was observed in 4.5% of patients, independently of the device used for PFO closure. The only difference reported after Figulla device implantation was a lower rate of supraventricular arrhythmias (9% vs. 17%, p=0.02).

CONCLUSIONS: According to this two-centre study, PFO closure appears safe and effective with the Figulla occluder as well as with the Amplatzer device.

Original languageEnglish
Publication statusE-pub ahead of print - Dec 20 2016


  • Journal Article


Dive into the research topics of 'Amplatzer versus Figulla occluder for transcatheter patent foramen ovale closure'. Together they form a unique fingerprint.

Cite this